Moonlake Immunotherapeutics (MLTX) Stock Price, Quote & News

Company Profile

MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerla...

Industry: Biotechnology

Sector: Healthcare

Phone: 41 415108022

Website: www.moonlaketx.com

Address:

Dorfstrasse 29, Zug, Switzerland

Modern_portholio_theory May. 15 at 8:33 PM

$MLTX two full weeks until the start of june

0 · Reply

LouKojak May. 15 at 8:19 PM

$MLTX

0 · Reply

Cardwizard May. 15 at 8:08 PM

$MLTX I lost a lot of fucking money in this motherfucker today. I am most certainly gonna be all booed up the entire weekend,, prescriptions and booze. That’s the only way I’m gonna get through this shit until next week.

3 · Reply

InsuranceSalesman May. 15 at 7:58 PM

$MLTX So Goldman dramatically increased their owned shares yet maintain a SELL rating with price target raised to $11 from $10. Make it make sense!

1 · Reply

WallStWolf38 May. 15 at 7:53 PM

$MLTX bought some more to support the people with 17,50 calls 😅

1 · Reply

Shaybe16569 May. 15 at 7:45 PM

$MLTX brutal

1 · Reply

Rockybhai7239 May. 15 at 7:15 PM

$MLTX $MLTX 13F filings looking VERY strong. Deep Track now holds 6.4M shares, Janus up 64%, Goldman up 317%, and institutional accumulation continues ahead of HS 52-week + IZAR-1 catalysts. Smart money appears to be positioning before data, not after. Float getting tighter while SLK setup keeps improving. 👀

2 · Reply

Rockybhai7239 May. 15 at 6:59 PM

$MLTX

0 · Reply

FlyingChemist01 May. 15 at 6:57 PM

$MLTX i have a feeling we might get to see the results this weekend, I don't know why...

2 · Reply

raticals May. 15 at 6:51 PM

$MLTX Goldman Sachs reporting 1.13 million shares up 317% is poetic

2 · Reply

MoonLake price target raised to $45 from $40 at H.C. Wainwright

2026-05-10T19:10:05.000Z - 5 days ago

MoonLake FDA meeting yields ‘best-in-class’ label, says Clear Street

2026-05-10T18:50:45.000Z - 5 days ago

MoonLake says aligned with FDA on submission plans for sonelokimab

2026-05-10T18:50:05.000Z - 5 days ago

MoonLake Immunotherapeutics reports Q1 EPS -98c vs. -91c last year

May 10, 2026, 9:00 AM EDT - 5 days ago

MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results

2026-03-29T14:35:05.000Z - 6 weeks ago

MoonLake Immunotherapeutics announces results from Phase 3 VELA-1, VELA-2 trial

Mar 28, 2026, 3:00 PM EDT - 6 weeks ago

MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting

2026-03-26T17:25:33.000Z - 7 weeks ago

MoonLake Immunotherapeutics management to meet with BTIG

2026-03-23T09:45:29.000Z - 7 weeks ago

MoonLake upgraded to Outperform from Underperform at Wolfe Research

2026-03-19T08:50:28.000Z - 2 months ago

MoonLake upgraded to Buy from Neutral at Rothschild & Co Redburn

2026-03-11T10:36:37.000Z - 2 months ago

MoonLake price target raised to $70 from $45 at Clear Street

2026-03-02T11:16:18.000Z - 2 months ago

MoonLake Immunotherapeutics price target raised to $40 from $32 at H.C. Wainwright

2026-02-26T12:31:16.000Z - 2 months ago

MoonLake Immunotherapeutics price target raised to $11 from $10 at Goldman Sachs

2026-02-24T12:54:10.000Z - 2 months ago

MoonLake Immunotherapeutics price target raised to $35 from $30 at Oppenheimer

Feb 23, 2026, 8:00 AM EST - 2 months ago

MoonLake Immunotherapeutics Transcript: Investor Day 2026

2026-02-22T19:15:48.000Z - 2 months ago

MoonLake announces results from Phase 2 trial of Sonelokimab

Feb 10, 2026, 7:00 AM EST - 3 months ago

ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer

IMA

2026-02-02T13:05:34.000Z - 3 months ago

MoonLake announces FDA granted Fast Track designation for sonelokimab

Feb 2, 2026, 8:00 AM EST - 3 months ago

MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day

Jan 27, 2026, 7:30 AM EST - 3 months ago

Helix Acquisition Corp. III Announces Closing of $172.5 Million Initial Public Offering, Including the Full Exercise of the Underwriter's Option to Purchase Additional Shares

Jan 23, 2026, 7:30 AM EST - 4 months ago

Helix Acquisition Corp. III Announces Pricing of Upsized $150 Million Initial Public Offering

2026-01-14T22:10:14.000Z - 4 months ago

MoonLake Immunotherapeutics downgraded to Sell from Neutral at Goldman Sachs

2026-01-09T11:15:53.000Z - 4 months ago

MoonLake price target raised to $32 from $26 at H.C. Wainwright

2026-01-09T11:00:21.000Z - 4 months ago

MoonLake Immunotherapeutics upgraded to Buy from Neutral at BTIG

2026-01-08T14:40:29.000Z - 4 months ago

Unusually active option classes on open January 8th

ACIC AVAV BABA DNN KTOS NOK RCAT

Dec 11, 2025, 8:54 AM EST - 5 months ago

DEADLINE NEXT WEEK: Berger Montague Advises MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors to Contact the Firm Before December 15, 2025

Dec 5, 2025, 8:18 AM EST - 5 months ago

MoonLake Immunotherapeutics (MLTX) Investors are Encouraged to Act before the Upcoming December 15 Securities Fraud Deadline – Contact BFA Law if You Lost Money

Dec 3, 2025, 7:46 AM EST - 5 months ago

MLTX NEWS: MoonLake Immunotherapeutics Sued for Securities Fraud after Stock Plummets 90% -- Investors Notified to Contact BFA Law by December 15 Deadline

Dec 1, 2025, 3:18 PM EST - 5 months ago

MLTX SHAREHOLDERS: MoonLake Immunotherapeutics Investors with Losses may have been Misled by the Company and are Urged to Contact BFA Law by December 15

Nov 30, 2025, 7:45 AM EST - 5 months ago

MLTX LAWSUIT: BFA Law Reminds MoonLake Immunotherapeutics Investors the Company has been Sued for Securities Fraud and to Contact BFA Law by December 15 Deadline

Nov 24, 2025, 6:08 AM EST - 6 months ago

MOONLAKE NOTICE: MoonLake Immunotherapeutics (MLTX) Faces Securities Fraud Allegations after Stock Drops 90%, Investors Urged to Contact BFA Law

Nov 14, 2025, 6:08 AM EST - 6 months ago

MOONLAKE INVESTORS: MoonLake Immunotherapeutics (MLTX) has been Sued for Securities Fraud, Investors are Urged to Contact BFA Law

Nov 10, 2025, 8:15 AM EST - 6 months ago

MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ: MLTX) DEADLINE ALERT Bernstein Liebhard LLP Reminds MoonLake Immunotherapeutics Investors of Upcoming Deadline

Nov 10, 2025, 6:06 AM EST - 6 months ago

MLTX STOCK NOTICE: MoonLake Immunotherapeutics Investors with Losses may have been Misled by the Company and are Urged to Contact BFA Law by December 15 Deadline

Nov 5, 2025, 7:11 AM EST - 6 months ago

MoonLake Immunotherapeutics Announces Pricing of $75 Million Underwritten Offering

Nov 5, 2025, 7:00 AM EST - 6 months ago

MoonLake Immunotherapeutics Reports Third Quarter 2025 Financial Results and Announces New Data from Clinical Trials of its Nanobody® Sonelokimab

Nov 1, 2025, 7:08 AM EDT - 6 months ago

MLTX INVESTOR REMINDER: MoonLake Immunotherapeutics Investors may have been Affected by Fraud -- Contact BFA Law if You Suffered Losses

Modern_portholio_theory May. 15 at 8:33 PM

$MLTX two full weeks until the start of june

0 · Reply

LouKojak May. 15 at 8:19 PM

$MLTX

0 · Reply

Cardwizard May. 15 at 8:08 PM

3 · Reply

InsuranceSalesman May. 15 at 7:58 PM

$MLTX So Goldman dramatically increased their owned shares yet maintain a SELL rating with price target raised to $11 from $10. Make it make sense!

1 · Reply

WallStWolf38 May. 15 at 7:53 PM

$MLTX bought some more to support the people with 17,50 calls 😅

1 · Reply

Shaybe16569 May. 15 at 7:45 PM

$MLTX brutal

1 · Reply

Rockybhai7239 May. 15 at 7:15 PM

2 · Reply

Rockybhai7239 May. 15 at 6:59 PM

$MLTX

0 · Reply

FlyingChemist01 May. 15 at 6:57 PM

$MLTX i have a feeling we might get to see the results this weekend, I don't know why...

2 · Reply

raticals May. 15 at 6:51 PM

$MLTX Goldman Sachs reporting 1.13 million shares up 317% is poetic

2 · Reply

LouKojak May. 15 at 6:44 PM

$MLTX this might be the lowest we see this stock ever again. Nothing is guaranteed but after today's opex and VERY bullish insider and institution buying news, with the 52 week Vela trial data is due and day from now to about June 30, it could be all ⬆️💰 from here.

0 · Reply

Obidagreat May. 15 at 6:34 PM

$MLTX Cormorant Asset Management back over 5%.

0 · Reply

psytrance May. 15 at 6:32 PM

$MLTX picked up 100 more

0 · Reply

CynicalDog May. 15 at 6:04 PM

$MLTX The manipulation on this stock is proportional to the losses during the sudden decline at the end of September 2025. The big fish, having lost a lot, are the same ones today who make up for it with a few percentages of profit per day. the facts, they remain bullish. Paytience

0 · Reply

LouKojak May. 15 at 6:04 PM

$MLTX finished rebuying. Back to 100%. Today was a gift along with insider updates. Super

0 · Reply

rrobers6 May. 15 at 5:39 PM

$MLTX Assuming we will get an amended 13g for Deep Track as well.

2 · Reply

AXMO May. 15 at 5:34 PM

$MLTX new filling https://ir.moonlaketx.com/sec-filings/sec-filing/schedule-13ga/0001172661-26-002221

2 · Reply

Joe_90_ May. 15 at 5:29 PM

$MLTX value

0 · Reply

maildriver May. 15 at 4:51 PM

$MLTX picked up a 4000 at 17.58 I wanted 17.12 but holding up better than I thought it would. Will sell at 18.08 for 2,000 gain

1 · Reply

Newcar May. 15 at 4:41 PM

$MLTX We must hope that all future clinical trial results are positive. A single conflicting finding (remember VELA 2?) would be enough to bring the price back to $6-$7.

1 · Reply

Mr_GA May. 15 at 4:17 PM

$MLTX https://youtu.be/UYZ4kc2tpck?si=Y5wQf5whwp7Ajt_f

1 · Reply

Jkm11 May. 15 at 4:08 PM

$MLTX the bottom is in i think..

1 · Reply

Market Cap	1.32B
Revenue (ttm)	0.00
Net Income (ttm)	-227.32M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.24

Volume	576,718
Avg Vol	1,058,180
Day's Range	N/A - N/A
Shares Out	71.73M
Stochastic %K	42%
Beta	1.01
Analysts	Strong Sell
Price Target	$30.18